Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice, yet treatment effectiveness has progressively declined worldwide because of increasing antibiotic resistance and challenges related to treatment adherence.
Introduction:
Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice, yet treatment effectiveness has progressively declined worldwide because of increasing antibiotic resistance and challenges related to treatment adherence. These concerns have transformed H. pylori management into an evolving global public health issue.
Problem Statement:
The effectiveness of conventional eradication regimens is increasingly compromised by rising resistance to commonly used antibiotics, including macrolides, nitroimidazoles, and other key agents. In addition, poor antibiotic penetration into the gastric mucosa, bacterial biofilm formation, efflux pump activity, and the complexity of multidrug treatment regimens contribute to eradication failure. Marked geographic variation in resistance patterns further complicates the selection of optimal therapy.
Summary:
This review examines the growing challenge of antimicrobial resistance in H. pylori management and highlights the importance of region-specific treatment strategies. The authors emphasize that resistance patterns vary considerably across different parts of the world, making empirical treatment approaches increasingly unreliable. Consequently, local resistance epidemiology should play a greater role in guiding eradication regimens. Beyond traditional antibiotic combinations, the review explores several emerging approaches designed to overcome current limitations. Novel drug-delivery systems, including gastro-retentive formulations and nanotechnology-based therapies, aim to improve antibiotic concentration and retention at the gastric mucosa, potentially enhancing eradication success. The review also discusses non-antibiotic strategies that may reduce reliance on conventional antimicrobials and help mitigate further resistance development. These innovative approaches seek not only to improve eradication rates but also to address the biological mechanisms that allow H. pylori to persist despite therapy. Overall, the review underscores that future management of H. pylori infection will likely require a combination of antimicrobial stewardship, personalized regional treatment algorithms, and innovative therapeutic technologies. As resistance continues to rise globally, integrating these emerging strategies into clinical practice may become essential for maintaining effective eradication and reducing the long-term burden of H. pylori-related disease.
Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...
Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...
Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...
Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...
Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...
Introduction Helicobacter pylori Infection remains a major global cause of peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Rising antimicrobial resistance, particularly to clarithromycin, has progressively reduced eradication success with conventional triple therapy....
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.